Predicted protein targets (top 4)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | KMT2A | Q03164 | 1/20 | 0.66 |
| ▸ | OPRM1 | P35372 | 5/20 | 0.59 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.46 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.44 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL10526309 | 0.85 | KDM1A (0.46) | KMT2AOPRM1ALDH1A1 | |
| SCHEMBL16591357 | 0.83 | KMT2A (0.68) | KMT2AOPRM1 | |
| SCHEMBL626449 | 0.82 | KDM1A (0.43) | KMT2AOPRM1ALDH1A1 | |
| SCHEMBL1018956 | 0.82 | SLC6A4 (0.46) | KMT2AOPRM1ALDH1A1 | |
| SCHEMBL5758344 | 0.82 | KMT2A (0.66) | KMT2AOPRM1 | |
| SCHEMBL14041008 | 0.81 | KMT2A (0.61) | KMT2AOPRM1 | |
| SCHEMBL4657165 | 0.81 | OPRM1 (0.71) | KMT2AOPRM1ALDH1A1 | |
| SCHEMBL1020648 | 0.81 | SLC6A4 (0.49) | KMT2AALDH1A1 | |
| SCHEMBL2227341 | 0.81 | KMT2A (0.64) | KMT2AOPRM1 | |
| SCHEMBL504355 | 0.80 | OPRM1 (0.70) | KMT2AOPRM1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-1549615-B1 | NAPHTHAMIDE DERIVATIVES AND THEIR USE | ASTRAZENECA AB (SE) | 2008-12-03 | — | — | EP | disclosed |
| US-20060241142-A1 | Naphthamide derivatives and their use | ALEATEL WIRELESS, INC. | 2006-10-26 | — | — | US | disclosed |
| EP-1549615-A1 | NAPHTHAMIDE DERIVATIVES AND THEIR USE | AstraZeneca AB (SE) | 2005-07-06 | — | — | EP | disclosed |
| WO-2004020411-A1 | NAPHTHAMIDE DERIVATIVES AND THEIR USE | ASTRAZENECA AB (SE) | 2004-03-11 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20060241142-A1 | Naphthamide derivatives and their use | NPM1, H1-4, H1-3 | KMT2A 979/4885OPRM1 696/4885ALDH1A1 1260/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.